ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
A human trial of oral BPC-157 was quickly canceled
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="sammmy" data-source="post: 271854" data-attributes="member: 38594"><p>BPC-157 and its drug delivery variations have quite a few patents already.</p><p></p><p>If there was a "lack of funding" then they wouldn't start a Phase 1 trial and complete it, which is extremely cheap in Mexico. Since the trial was completed and the results not published, the only logical conclusion is that they didn't like the results.</p></blockquote><p></p>
[QUOTE="sammmy, post: 271854, member: 38594"] BPC-157 and its drug delivery variations have quite a few patents already. If there was a "lack of funding" then they wouldn't start a Phase 1 trial and complete it, which is extremely cheap in Mexico. Since the trial was completed and the results not published, the only logical conclusion is that they didn't like the results. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
A human trial of oral BPC-157 was quickly canceled
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top